The first patients have been dosed in a Phase I/II trial of Domain Therapeutics’ DT-7012 targeting CCR8 in solid cancer tumours 

DT-7012 is a novel immunotherapy candidate designed to selectively deplete intra-tumoural regulatory T cells (Tregs) by targeting CCR8, a receptor predominantly expressed on Tregs within the tumour microenvironment (TME).  

Leveraging potent ADCC and ADCP mechanisms, DT-7012 effectively eliminates these immunosuppressive cells, transforming the TME into a more immunocompetent state. 

By disrupting CCR8-mediated immunosuppressive environment, DT-7012 promotes tumour regression, offering a potential new treatment option to patients unresponsive to existing immunotherapies. 

The DOMISOL study is an open-label, multicentre Phase I/II, first-in-human dose-escalation and cohort-expansion trial evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumour activity of DT-7012 in adult patients with selected advanced solid tumours. 

The trial is being conducted in Australia, with initial clinical sites including Peninsula and Southeast Oncology (PASO) and Cabrini Health in Melbourne.  

“CCR8 has rapidly emerged as a highly competitive target, drawing significant interest across the industry, including from leading pharmaceutical companies,” said Stephan Schann, Chief Scientific Officer of Domain Therapeutics. 

“DT-7012 stands out with its unique and differentiating properties, offering unprecedented selectivity in depleting intra-tumoural Tregs while simultaneously improving overall immune system function. These features are critical for effective cancer immunotherapy, positioning DT-7012 as a promising candidate to overcome immune resistance and bring hope to patients with limited treatment options.” 

Sean MacDonald, Chief Executive Officer of Domain Therapeutics, added: “Dosing of the first patients in the DOMISOL trial represents a significant milestone, as
DT-7012 becomes our second fully proprietary asset to enter the clinic, underscoring our proven ability to translate cutting-edge GPCR biology into high value differentiated products.” 


Bruno Quinney, Content Team, DDW